Voloridge Investment Management LLC Makes New Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Voloridge Investment Management LLC purchased a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 18,321 shares of the biopharmaceutical company's stock, valued at approximately $876,000.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Heck Capital Advisors LLC bought a new stake in Halozyme Therapeutics in the 4th quarter valued at $29,000. CBIZ Investment Advisory Services LLC bought a new position in Halozyme Therapeutics in the fourth quarter worth $29,000. Smartleaf Asset Management LLC boosted its stake in Halozyme Therapeutics by 29.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock worth $42,000 after buying an additional 197 shares in the last quarter. Venturi Wealth Management LLC bought a new stake in Halozyme Therapeutics in the 4th quarter valued at $69,000. Finally, Parkside Financial Bank & Trust raised its stake in shares of Halozyme Therapeutics by 21.8% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock valued at $86,000 after buying an additional 322 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company's stock.

Wall Street Analysts Forecast Growth

HALO has been the topic of a number of analyst reports. HC Wainwright reissued a "buy" rating and issued a $72.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, May 29th. JPMorgan Chase & Co. increased their target price on Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a "neutral" rating in a report on Monday, April 21st. Leerink Partnrs lowered Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Tuesday, May 13th. Morgan Stanley lowered Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and dropped their price objective for the stock from $73.00 to $62.00 in a research note on Wednesday, May 14th. Finally, Wells Fargo & Company boosted their target price on shares of Halozyme Therapeutics from $60.00 to $65.00 and gave the company an "equal weight" rating in a research note on Wednesday, May 7th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $61.90.

Halozyme Therapeutics Trading Down 3.6%

Shares of NASDAQ:HALO traded down $2.02 during trading on Tuesday, hitting $53.62. 795,179 shares of the company's stock were exchanged, compared to its average volume of 1,830,258. The firm has a 50-day moving average price of $58.74 and a two-hundred day moving average price of $55.73. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14. Halozyme Therapeutics, Inc. has a 1-year low of $42.01 and a 1-year high of $70.50. The firm has a market cap of $6.61 billion, a P/E ratio of 15.63, a PEG ratio of 0.42 and a beta of 1.26.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.13. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The business had revenue of $264.86 million for the quarter, compared to analyst estimates of $231.21 million. During the same period last year, the company earned $0.79 EPS. The firm's revenue was up 35.2% on a year-over-year basis. Equities analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Insider Buying and Selling

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 4,497 shares of Halozyme Therapeutics stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $60.37, for a total transaction of $271,483.89. Following the transaction, the director now directly owns 28,611 shares in the company, valued at approximately $1,727,246.07. The trade was a 13.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 2.40% of the stock is owned by insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.